Insmed Incorporated
http://www.insmed.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Insmed Incorporated
With A Transformational Year Underway, Insmed Ramps Up
With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.
AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.
Evaxion Cancer Vaccines Excite Investors
Shares in the Danish biotech have soared by 110% over plans to prioritize a novel category of AI-identified tumor antigens for its cancer vaccines.
What Do FTC’s Aggressive Moves Against Biopharma Portend For 2024?
The Federal Trade Commission blocked or restricted several deals last year, broadening what it considers to be anticompetitive transactions. Stakeholders are looking to see if the agency will bring similar cases this year and what remedies it will seek to allow deals to go forward.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Liposomes
- Other Names / Subsidiaries
-
- Insmed, Inc.
- Transave Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice